Holmium laser enucleation of the prostate: morbidity in a series of 206 patients.

OBJECTIVES: To review the complications associated with 206 holmium laser enucleation of the prostate (HoLEP) procedures. HoLEP is a minimally invasive surgical treatment for benign prostatic hyperplasia. METHODS: A retrospective review was conducted of HoLEPs performed from April 1, 1999 to October 1, 2001. Patients with previous diagnoses of prostate carcinoma or who had undergone HoLEP after admission for unrelated problems were excluded. Demographic, intraoperative, and immediate postoperative data were recorded to determine the incidence of complications. Patients were also contacted by telephone or mailed surveys for documentation of longer term complications. RESULTS: The mean age and procedure time was 70.5 years (range 45 to 91) and 133.6 minutes (range 25 to 473), respectively. The mean specimen weight was 68.2 g (range 3 to 376), with 20 (9.7%) of 206 patients diagnosed with adenocarcinoma. The mean hospital stay was 1.1 days, with 86.9% of patients discharged after an overnight stay without a catheter. Two patients required postoperative transfusions (1.0%). No deaths, major complications (myocardial infarction or pulmonary embolism), or transurethral resection syndrome episodes occurred. Intraoperative complications consisted of three capsular perforations (1.5%), one bladder neck false passage (0.5%), four incomplete morcellations (1.9%), and four minor bladder mucosal morcellation injuries (1.9%). Of 206 patients, 173 (84.0%) provided follow-up data (mean 19.0 +/- 8.4 months), allowing documentation of longer term complications, including five clot retention episodes (2.4%), five urethral strictures (2.4%), eight bladder neck contractures (3.9%), and 16 patients requiring re-catheterization (7.8%). CONCLUSIONS: HoLEP can be performed with minimal complication risks and blood loss. Patients can expect an overnight hospital stay and discharge without an indwelling catheter.

Holmium laser enucleation of prostate (HoLEP): the Methodist Hospital experience with greater than 75 gram enucleations.

PURPOSE: Holmium laser enucleation of the prostate (HoLEP) effectively removes obstructive prostate tissue in minimally invasive fashion. We present our large enucleation outcomes (greater than 75 gm retrieved). We examined post-procedural prostate specific antigen (PSA) and transrectal ultrasound (TRUS) volume changes to assess tissue removal completeness. MATERIALS AND METHODS: We retrospectively reviewed HoLEPs performed from April 1, 1999 through September 30, 2002 to identify all enucleations greater than 75 gm. Demographic, laboratory, operative and pathological data were obtained. Patients were surveyed to document longer term complications. RESULTS: The cohort of 108 patients had a mean age and specimen weight of 71.5 years (range 53 to 90) and 120.6 gm (range 75.3 to 376), respectively. Average procedural time and hospital stay were 166.8 minutes (range 75 to 473) and 1.2 days (range 0 to 4), respectively. No deaths or episodes of transurethral resection syndrome occurred. Postoperative complications included transfusion in 2 cases, a clot retention episode in 3, capsular perforation in 2, morcellator blade malfunction in 4, minor bladder mucosal injury in 1 and bladder neck contracture in 1. American Urological Association symptom scores reassessed in 53 patients without chronic retention an average +/- SD of 10.6 +/- 7.1 months postoperatively showed a mean decrease from 20.3 +/- 6.4 to 4.7 +/- 3.8. PSA in 48 patients a mean of 5.0 +/- 4.1 months postoperatively had decreased an average of 91.7%. In 10 patients TRUS data revealed a mean post-procedural volume decrease of 85.9%. CONCLUSIONS: HoLEP can be performed on extremely large prostates with minimal risk or need for secondary interventions. Most patients are discharged home after an overnight stay. Postoperative decreases in PSA and TRUS volumes support the completeness of enucleation that can be achieved.

The Indiana experience with artificial urinary sphincters in children and young adults.

PURPOSE: We reviewed a 22-year single institutional experience with the artificial urinary sphincter in children and adolescents. To our knowledge this report represents the largest series in the world in children. MATERIALS AND METHODS: Between 1980 and 2002, 142 patients underwent implantation of an artificial urinary sphincter, of whom 93 males and 41 females with a median age of 10 years (range 3 to 39) were available for analysis. A total of 59 patients initially received an AMS 742/792 (American Medical Systems, Inc., Minnetonka, Minnesota) artificial urinary sphincter, of whom 33 were subsequently changed to an AMS 800, while 75 initially received an AMS 800 model. Sphincter followup was terminated at device removal or at the last documented contact. The etiology of incontinence was neuropathic bladder in 107 cases (80%), the exstrophy/epispadias complex in 21 (16%) and other in 6 (4%). Outcome measures included continence, mechanical complications (leakage, tube kink and pump malfunction), functioning sphincter revisions (change in cuff size, pump repositioning and bulbar cuff placement), surgical complications (erosion, infection and misplacement) and associated surgical procedures. Mean followup of the pre-800 and 800 models was 6.9 (range 0.2 to 21.5) and 7.5 years (range 0.1 to 17.1), respectively. Fisher's exact test, Kaplan-Meier life analysis and the chi-square test were used for statistical analysis. RESULTS: After artificial urinary sphincter placement in the 134 patients continence was achieved in 86%, improved in 4% and not achieved in 10%. Of those with a sphincter in place 92% were continent. In terms of bladder emptying after artificial urinary sphincter insertion 22% of patients voided, 11% voided combined with clean intermittent catheterization, 48% performed clean intermittent catheterization only via the urethra, 16% performed it via a catherizable channel and 3% used urinary diversion. A mechanical complication developed in 38 of the 59 patients (64%) with pre-800 model compared with 33 of the 109 (30%) with the 800 model (p <0.0001). A mechanical complication occurred every 7.6 versus 16 patient-years for the pre-800 versus 800 models (p = 0.0001). Revision was required in 15 of the 59 patients (25%) with a pre-800 model versus 17 of the 109 (16%) with the 800 model (p = 0.103). Revision was performed every 22.7 versus 44.3 patient-years for the pre-800 versus the 800 model (p = 0.023). The artificial urinary sphincter eroded in 11 of the 59 patients (19%) with the pre-800 versus 17 of the 109 (16%) with the 800 model (p = 0.52). Ten patients experienced a total of 12 perforations of the augmented bladder after artificial urinary sphincter implantation. A total of 164 secondary surgical procedures were performed, including 38 of 134 bladder augmentations (28%). A total of 30 sphincters were permanently removed. CONCLUSIONS: The artificial urinary sphincter is the only bladder neck procedure that allows spontaneous voiding in the neuropathic population, obviates the need for clean intermittent catheterization and yet is compatible with it when necessary. It is also equally versatile in the 2 genders. Mechanical complications occur but they were dramatically decreased by the modifications of the AMS 800 model. In addition, secondary bladder augmentation was required in 28% of our patients. Lifelong followup is mandatory in all patients with an artificial urinary sphincter.

Salvage procedure for infected noneroded artificial urinary sphincters.

PURPOSE: We report our experience with removal, antiseptic irrigation and immediate reimplantation of infected noneroded artificial urinary sphincters. MATERIALS AND METHODS: From April 1996 to October 2000, 8 patients with an infected artificial urinary sphincter underwent a total of 9 salvage operations. All patients underwent cystoscopy before salvage to ensure nonerosion of the sphincter cuff. All previously implanted material was removed, the wounds were copiously irrigated according to a 7 solution protocol and an identical new system was implanted. All patients were discharged home the following morning on oral antibiotics. RESULTS: Followup was 5 to 66 months (mean 33). The predominant organisms cultured at salvage were gram-positive cocci. Time from implantation to salvage was from 2 weeks to 64 months (mean 13.7 months). Prostatectomy was the etiology of incontinence in all except 1 case. In 5 of the 8 men a double cuff system was placed and 3 underwent concurrent 3-piece inflatable penile prosthesis salvage. The salvage procedure was done twice in 1 patient 5 months apart. The system was removed 16 months later secondary to urethral erosion. At the most recent followup the other 7 patients were free of infection with a functioning artificial urinary sphincter. CONCLUSIONS: Salvage and immediate reimplantation of an infected, noneroded single or double cuff artificial urinary sphincter appears to be a valid option. Our overall success rate was 87%. The usual offending organisms are gram-positive skin flora. An associated inflatable penile prosthesis does not prohibit simultaneous salvage of the 2 devices.